You are here

The Development of a Bimodal Walking-Running Prosthetic Foot

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44HD113432-01
Agency Tracking Number: R44HD113432
Amount: $1,142,863.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NICHD
Solicitation Number: PA22-177
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-09-19
Award End Date (Contract End Date): 2025-08-31
Small Business Information
Holliston, MA 01746-1456
United States
DUNS: 050467997
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (774) 233-0874
Business Contact
Phone: (774) 233-0873
Research Institution

Over the course of this two-year Phase II effort, Liberating Technologies, Inc. (LTI), along with its collaborators
at Fillauer Companies and Hanger Clinic, will refine, expand, and test a bimodal walking-running foot that would
then be poised to become a viable commercial product that can be reimbursed under the existing L-code
reimbursement structure. The goal of this project is to create a single foot that is optimized in each mode and
comparable to a walking foot when in a walking mode and a running foot when in running mode. This novel foot
would provide lower limb amputees who don’t currently have the access to running feet due to the lack of
insurance coverage, the opportunity to participate in running and other running-based activities (e.g. basketball,
etc.) to increase physical fitness. In doing so, the Caesar foot would also allow for the increased social
participation and the physical and mental health benefits that are associated with these activities.
In order to achieve this goal, we will progress and refine the bimodal foot technology with the achievement of the
following objectives: (1) iterate and optimize the design of the bimodal foot to achieve a fully functional prototype
ready for testing, (2) perform verification testing to confirm the prototype meets the design criteria, (3) validate
the prototype in a pilot take-home trial and assess its impact on the physical activity of lower limb amputees, and
(4) start preparing for an FDA submission for the Caesar foot.
The outcomes will be data that verify and validate the bimodal foot device in the laboratory and in the real world.
The product will be a highly advanced, commercially viable, verified, and validated bimodal prosthetic foot. This
innovative design allows us to address both of the identified primary barriers preventing LLAs from taking part in
these activities: 1) inadequately designed prostheses (by providing a foot with optimized design, alignment, and
biomechanics in both walking and running modes) and 2) the lack of accessibility for higher activity prostheses
(the cost of the foot would be covered by insurance).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government